BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Fenofibrate
,
rs4950928
,
VEGFA
,
Response to oxidative stress
,
Influenza
,
Prostate
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
interleukin- ii
Summary
General Info
Curated Studies
Most Correlated Studies
L1000 CMAP - Carcinoma of prostate PC3 cells treated with ligand perturbagens
L1000 CMAP - Prostate carcinoma VCaP cells treated with ligand perturbagens
L1000 CMAP - Embryonic kidney epithelial HA1E cells treated with ligand perturbagens
L1000 CMAP - Lung cancer A549 cells treated with ligand perturbagens
L1000 CMAP - Non-small cell lung cancer HCC515 cells treated with ligand perturbagens
Explore Curated Studies Results
Literature
Most Relevant Literature
Interleukin-2-based therapies in cancer.
The soluble IL-2 receptor α/CD25 as a modulator of IL-2 function.
Interleukin-2 signaling in the regulation of T cell biology in autoimmunity and cancer.
Fine tuning of the innate and adaptive immune responses by Interleukin-2.
Comparison of IL-2-antibody to IL-2-Fc with or without stereotactic radiation therapy in CEA immunoc…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
A Phase I/II Study of Recombinant Interleukin-4 in AIDS and Kaposi's Sarcoma
Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell…
Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recur…
A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumo…
Phase II Trial of Monoclonal Antibody (J591) in Combination With Low-Dose Subcutaneous Interleukin-2
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ